We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.


Belluscura aims at attending millions of people worldwide who are suffering from chronic lung diseases by providing them with the X-PLOR, portable, a lightweight, oxygen delivery device. It has developed it mainly to improve both the mobility and the life quality of the patients suffering from Chronic Obstructive Pulmonary Disease globally. It also has an exclusive license to a patented portable oxygen concentrator, the X-PLOR, that supplies 96% pure oxygen to patients 24/7. It's X-PLOR weights only 1.4kg and is 33% lighter, and provides 37% more oxygen per kg than its leading opponents. As smoke, pollution, and lives increase, the oxygen market will continue to grow from £1.1bn to £1.9bn by 2024. So, according to its market research, a 3% market share within 3 years could generate £46m in sales. With the funds raised, it is planning to extend its proprietary oxygen platform technology into other multi £bn markets such as wound care and sleep. Furthermore, it has filed patents on a next-generation portable artificial lung.

  • £543,670
    raised of £500,000 goal
  • Expired
    03 May 2019
  • Please Login to see equity offered
    maximum equity offered
  • 335
  • 8.98%
    equity offered
  • £5,067,335
    pre-money valuation
  • 10/12/2015
    incorporated 4 years ago
  • Crowdcube
  • Medical EIS
View on Crowdcube businessagent.com may earn a commission from partners

The content below is news from around the world relating to @Belluscura

The below content is from social media taken from external sites and is not representative of the views of businessagent.com or Belluscura.

Twitter feed: @Belluscura

Please sign in or register to businessagent.com to comment on this pitch.

Sign In Register
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph